Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study.docVIP

Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study Caitrin W. McDonough , Jason E. Lang , Taimour Y. Langaee T. Turner , Yan Gong , Julie A. Johnson 1,6* 1 , Nancy K. Gillis , Mohamed Hossam A. Shahin , John G. Gums , Arlene B. Chapman 1 , Abdullah Alsultan , Thomas W. Buford , Rhonda M. Cooper-DeHoff 1,6 1 , Shin-Wen Chang , Nihal M. El Rouby , Stephen 1 , Marina Kawaguchi- Suzuki 1 2 1 3 1 , Ana C.C. Sá 1 1 1,4 5 7 1 1 Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, College of Pharmacy, Gainesville, Florida, United States of America, 2 Division of Pulmonary and Sleep Medicine and Center for Pharmacogenomics and Translational Research, Nemours Children’s Hospital, Orlando, Florida, United States of America, 3 Department of Aging and Geriatric Research, University of Florida, College of Medicine, Gainesville, Florida, United States of America, 4 Department of Community Health and Family Medicine, University of Florida, College of Medicine, Gainesville, Florida, United States of America, 5 The Renal Division, Department of Medicine, Emory University, Atlanta, Georgia, United States of America, 6 Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, Florida, United States of America, 7 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States of America Abstract We sought to identify novel pharmacogenomic markers for HDL-C response to atenolol in participants with mild to moderate hypertension. We genotyped 768 hypertensive participants from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study on the Illumina HumanCVD Beadchip. During PEAR, participants were randomized to receive atenolol or hydrochlorothiazide. Blood pressure and cholesterol levels were evaluated